Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Prognostic impact of cytogenetic abnormalities by FISH in AL amyloidosis with daratumumab-based frontline therapy

Rajshekhar Chakraborty, Saurabh Zanwar, Ute Hegenbart, Divaya Bhutani, Morie A Gertz, Angela Dispenzieri, Shaji K Kumar, Anita D'Souza, Anannya Patwari, Andrew J Cowan, GuiZhen Chen, Paolo Milani, Giovanni Palladini, Vaishali Sanchorawala, Geethika Bodanapu, Stefan Schönland, Suzanne Lentzsch, Eli Muchtar

Blood blood.2024025899.

https://doi.org/10.1182/blood.2024025899

Published: 2024

Includes: Supplemental data

Journal Articles

Reduced Early Mortality with Daratumumab-Based Frontline Therapy in Systemic AL Amyloidosis- Experience from the Columbia Amyloidosis Multidisciplinary Program

Rajshekhar Chakraborty, Divaya Bhutani, Markus Mapara, Ran Reshef, Mathew S Maurer, Jai Radhakrishnan, Suzanne Lentzsch

Blood (2023) 142 (Supplement 1): 4780.

https://doi.org/10.1182/blood-2023-187214

Published: 2023

Journal Articles

Teclistamab in Relapsed Refractory Multiple Myeloma: Multi-Institutional Real-World Study

Blood (2023) 142 (Supplement 1): 545.

https://doi.org/10.1182/blood-2023-174875

Published: 2023

Journal Articles

Outcomes Associated with Clone-Directed Therapies for Monoclonal Gammopathy of Renal Significance

Daniel T Peters, Jacob Amburn, Sascha Tuchman, Eben I Lichtman, Christopher Edward Jensen, Koyal Jain, Suzanne Lentzsch, Rajshekhar Chakraborty, Divaya Bhutani, Samuel M Rubinstein

Blood (2023) 142 (Supplement 1): 2027.

https://doi.org/10.1182/blood-2023-189341

Published: 2023

Journal Articles

Risk Stratification Models Overestimate Progression Risk in Contemporary Patients with Smoldering Multiple Myeloma (SMM)

George Mellgard, Molly Gilligan, Edward R Scheffer Cliff, Divaya Bhutani, Ghulam Rehman Mohyuddin, Andrew Eisenberger, Suzanne Lentzsch, Rajshekhar Chakraborty

Blood (2023) 142 (Supplement 1): 4768.

https://doi.org/10.1182/blood-2023-174908

Published: 2023

Journal Articles

Excellent PFS and OS of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib, Bendamustine, and Dexamethasone (KBD): A 6.5 Year Follow-up

Michael Sang Hughes, Siyang Leng, Rajshekhar Chakraborty, Divaya Bhutani, Markus Mapara, Shahzad Raza, Suzanne Lentzsch

Blood (2023) 142 (Supplement 1): 6576.

https://doi.org/10.1182/blood-2023-182842

Published: 2023

Journal Articles

The Impact of Hispanic Ethnicity on Disease Characteristics in Multiple Myeloma

Kara I. Cicero, Alfred I. Neugut, Andrew H. Doyle, Divaya Bhutani, Amer Assal, Ran Reshef, Markus Y. Mapara, Suzanne Lentzsch, Rajshekhar Chakraborty

Blood (2022) 140 (Supplement 1): 8026–8027.

https://doi.org/10.1182/blood-2022-166491

Published: 2022

Journal Articles

Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis

Camille Vanessa Edwards, Nisha Rao, Divaya Bhutani, Markus Mapara, Jai Radhakrishnan, Sofia Shames, Mathew S. Maurer, Siyang Leng, Alan Solomon, Suzanne Lentzsch, Andrew Eisenberger

Blood (2021) 138 (25): 2632–2641.

https://doi.org/10.1182/blood.2020009039

Published: 2021

Includes: Supplemental data

Journal Articles

Impact of Light Chain Isotype on Clinical Features and Outcomes in Systemic AL Amyloidosis

Madeleine Hopson, Divaya Bhutani, Shawn M Sarkaria, Mathew Maurer, Jan Griffin, Suzanne Lentzsch, Rajshekhar Chakraborty

Blood (2021) 138 (Supplement 1): 4726.

https://doi.org/10.1182/blood-2021-149299

Published: 2021

Journal Articles

Targeting the GCK pathway: a novel and selective therapeutic strategy against RAS-mutated multiple myeloma

Shirong Li, Jing Fu, Jun Yang, Huihui Ma, Divaya Bhutani, Markus Y. Mapara, Christophe Marcireau, Suzanne Lentzsch

Blood (2021) 137 (13): 1754–1764.

https://doi.org/10.1182/blood.2020006334

Published: 2021

Includes: Supplemental data

Journal Articles

Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase 1b Study

Erlene K. Seymour, MD, Yiwei Li, Amro Aboukameel, Radhakrishnan Ramchandren, Golbon Sterbis, Jay Yang, MD, Divaya Bhutani, MD, Ramzi Mohammad, PhD, Asfar Sohail Azmi, PhD, Jeff Zonder, MD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-140752

Published: 2020

Journal Articles

Severity of Sars-Cov-2 Infection in Patients with Hematologic Malignancies: A COVID-19 and Cancer Consortium (CCC19) Registry Analysis

Samuel Rubinstein, MD, Ryan C. Lynch, MD, Aakash Desai, MD, Catherine Stratton, MPH, Alokkumar Jha, PhD, Ziad Bakouny, MD MSc, Andrew Schmidt, MD, R. Alejandro Sica, MD, Divaya Bhutani, MD, Dimpy P. Shah, MD PhD, Sarah A Wall, MD, Gary H. Lyman, MD, Nicole M. Kuderer, MD MSc, Matthias Weiss, MD PhD, Jeremy L. Warner, MD MS, Keith E. Stockerl-Goldstein, MD, Ruben Mesa, MD, Michael A. Thompson, MD PhD

Blood (2020) 136 (Supplement 1): 28–30.

https://doi.org/10.1182/blood-2020-141937

Published: 2020

Journal Articles

Excellent Survival and Immune Reconstitution Following Matched/Mismatched Unrelated and Mismatched Related Transplantation in Adult Patients with Sickle Cell Disease: Updated Results from a Single Center Experience

Amer Assal, MD, Diane George, MD, Monica Bhatia, MD, Divaya Bhutani, MD, Christian Gordillo, BS, Suzanne Lentzsch, MD PhD, Ran Reshef, MDMSc, Markus Y Mapara, MD PhD

Blood (2019) 134 (Supplement_1): 2043.

https://doi.org/10.1182/blood-2019-132113

Published: 2019

Journal Articles

Treatment of Non-Amyloid Monoclonal Gammopathies of Renal Significance (MGRS) with Clone Directed Therapies-Single Center Experience

Divaya Bhutani, MD, Vikram Premkumar, MD, Shayan Shirazayan, MD, Andrew Bomback, MD, Jai Radhakrishnan, MD, Suzanne Lentzsch, MD PhD

Blood (2019) 134 (Supplement_1): 5565.

https://doi.org/10.1182/blood-2019-128455

Published: 2019

Journal Articles

Single Arm, Prospective, Open-Label Phase II Trial to Evaluate the Efficacy of Isatuximab in Patients with Monoclonal Gammopathy of Renal Significance

Vikram Premkumar, MD, Suzanne Lentzsch, MD PhD, Divaya Bhutani, MD

Blood (2019) 134 (Supplement_1): 3161.

https://doi.org/10.1182/blood-2019-123496

Published: 2019

Journal Articles

Combination Chemotherapy with Carfilzomib, Bendamustine and Dexamethasone Is Highly Active for Therapy of Newly Diagnosed Multiple Myeloma-Results of Single Center Phase I/II Study

Divaya Bhutani, MD, Siyang Leng, MD, Samuel Pan, Amer Assal, MD, Alexander Wei, Julia Gould, BA, Markus Y. Mapara, MD PhD, Suzanne Lentzsch, MD PhD

Blood (2019) 134 (Supplement_1): 3196.

https://doi.org/10.1182/blood-2019-130207

Published: 2019

Journal Articles

Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Chia-jen Liu, MD, Irene M. Ghobrial, MD, Mark Bustoros, MD, Kaitlen Reyes, NP, Kalvis Hornburg, BA, Ashraf Z. Badros, MD, James J. Vredenburgh, MD, Adam Boruchov, MD, Jeffrey V Matous, MD, Aaron Caola, BS, Bradley Rivotto, BS, Alexandra Savell, BS, Patrick Henrick, BS, Claudia E. Paba-Prada, MD, Robert L. Schlossman, MD, Jacob Laubach, MD, Jacalyn Rosenblatt, MD, Andrew J Yee, MD, Omar Nadeem, MD, Rodrigo O. Maegawa, MD, Andrzej Jakubowiak, MD PhD, Saad Z. Usmani, MD, Manisha Bhutani, MD, Joseph Cappuccio, BS, Brianna Berrios, BS, Kimberly Noonan, NP, Oksana Zavidij, PhD, Tarek H Mouhieddine, MD, Cody J Boehner, Carl-Jannes Neuse, Karma Ziad Salem, MD, Mairead Reidy, PhD, Jihye Park, PhD, Michael Agius, PhD, Mahshid Rahmat, PhD, Salomon Manier, MD PhD, Divaya Bhutani, MD, Jeffrey A Zonder, MD, Nikhil Munshi, MD, Daniel Auclair, PhD, Kenneth Anderson, MD, Paul Richardson

Blood (2018) 132 (Supplement 1): 154.

https://doi.org/10.1182/blood-2018-154

Published: 2018

Journal Articles

Improvement in Global Longitudinal Strain (GLS) Correlates with NT-Probnp Response in Patients with Cardiac Amyloidosis Treated on a Phase 1b Study of Anti-Amyloid Mab Cael-101

Divaya Bhutani, MD, Siyang Leng, MD, Andrew Eisenberger, MD, Mathew S. Maurer, MD, Sofia Shames, MD, Jeff Goldsmith, PhD, Suzanne Lentzsch, MD PhD

Blood (2018) 132 (Supplement 1): 958.

https://doi.org/10.1182/blood-2018-99-118464

Published: 2018

Journal Articles

Transaminase Elevation As a Marker of Liver GVHD Is Associated with Poor Survival Among Allogeneic Stem Cell Transplant Recipients

Dipenkumar Modi, MD, Wei Chen, Hyejeong Jang, Abhinav Deol, MD, Lois Ayash, MD, Asif Alavi, MD, Divaya Bhutani, MD, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD

Blood (2017) 130 (Supplement 1): 3275.

https://doi.org/10.1182/blood.V130.Suppl_1.3275.3275

Published: 2017

Journal Articles

Phase I Trial of Pomalidomide, Bortezomib, and Dexamethasone As Frontline Treatment of AL Amyloidosis

Jeffrey A Zonder, MD, Vaishali Sanchorawala, MD, Vishal Kukreti, MD FRCP(C), Sascha A Tuchman, MD, Yubin Kang, MD, Divaya Bhutani, MD, Steven Burt, ANP, Christiane Houde, BS, Kathy A. Reichel, Silva Pregja, MBA, Jeffrey V Matous, MD

Blood (2017) 130 (Supplement 1): 3158.

https://doi.org/10.1182/blood.V130.Suppl_1.3158.3158

Published: 2017

NARROW

Prognostic impact of cytogenetic abnormalities by FISH in AL amyloidosis with daratumumab-based frontline therapy

Reduced Early Mortality with Daratumumab-Based Frontline Therapy in Systemic AL Amyloidosis- Experience from the Columbia Amyloidosis Multidisciplinary Program

Teclistamab in Relapsed Refractory Multiple Myeloma: Multi-Institutional Real-World Study

Outcomes Associated with Clone-Directed Therapies for Monoclonal Gammopathy of Renal Significance

Risk Stratification Models Overestimate Progression Risk in Contemporary Patients with Smoldering Multiple Myeloma (SMM)

Excellent PFS and OS of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib, Bendamustine, and Dexamethasone (KBD): A 6.5 Year Follow-up

The Impact of Hispanic Ethnicity on Disease Characteristics in Multiple Myeloma

Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis

Impact of Light Chain Isotype on Clinical Features and Outcomes in Systemic AL Amyloidosis

Targeting the GCK pathway: a novel and selective therapeutic strategy against RAS-mutated multiple myeloma

Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase 1b Study

Severity of Sars-Cov-2 Infection in Patients with Hematologic Malignancies: A COVID-19 and Cancer Consortium (CCC19) Registry Analysis

Excellent Survival and Immune Reconstitution Following Matched/Mismatched Unrelated and Mismatched Related Transplantation in Adult Patients with Sickle Cell Disease: Updated Results from a Single Center Experience

Treatment of Non-Amyloid Monoclonal Gammopathies of Renal Significance (MGRS) with Clone Directed Therapies-Single Center Experience

Single Arm, Prospective, Open-Label Phase II Trial to Evaluate the Efficacy of Isatuximab in Patients with Monoclonal Gammopathy of Renal Significance

Combination Chemotherapy with Carfilzomib, Bendamustine and Dexamethasone Is Highly Active for Therapy of Newly Diagnosed Multiple Myeloma-Results of Single Center Phase I/II Study

Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Improvement in Global Longitudinal Strain (GLS) Correlates with NT-Probnp Response in Patients with Cardiac Amyloidosis Treated on a Phase 1b Study of Anti-Amyloid Mab Cael-101

Transaminase Elevation As a Marker of Liver GVHD Is Associated with Poor Survival Among Allogeneic Stem Cell Transplant Recipients

Phase I Trial of Pomalidomide, Bortezomib, and Dexamethasone As Frontline Treatment of AL Amyloidosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only